[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[3]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Sta-tistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[4]
|
赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京) [J]. 临床肝胆病杂志, 2022, 38(8): 1739-1758+1954-1967.
|
[5]
|
南月敏, 高沿航, 王荣琦, 李文刚, 赵素贤, 杨明. 原发性肝癌二级预防共识(2021年版) [J]. 临床肝胆病杂志, 2021, 37(3): 532-542.
|
[6]
|
Petrick, J.L., Florio, A.A., Znaor, A., et al. (2020) Interna-tional Trends in Hepatocellular Carcinoma Incidence, 1978-2012. International Journal of Cancer, 147, 317-330. https://doi.org/10.1002/ijc.32723
|
[7]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[8]
|
管颜青. 2040年全球肝癌新发病例将增55% [N]. 医师报, 2022-10-13(B02).
|
[9]
|
Park, J.W., Chen, M., Colombo, M., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International: Official Journal of the International Association for the Study of the Liver, 35, 2155-2166. https://doi.org/10.1111/liv.12818
|
[10]
|
Ryerson, A.B., Eheman, C.R., Altekruse, S.F., et al. (2016) Annual Report to the Nation on the Status of Cancer, 1975-2012, Featuring the Increasing Incidence of Liver Cancer. Cancer, 122, 1312-1337.
https://doi.org/10.1002/cncr.29936
|
[11]
|
原发性肝癌诊疗规范(2019年版) [J]. 中国实用外科杂志, 2020, 40(2): 121-138.
|
[12]
|
Sun, H.C., Zhou, J., Wang, Z., et al. (2022) Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition). Hepatobiliary Surgery and Nutrition, 11, 227-252. https://doi.org/10.21037/hbsn-21-328
|
[13]
|
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版) [J]. 中华消化外科杂志, 2021, 20(6): 600-616.
|
[14]
|
Zhu, S.L., Zhong, J.H., Ke, Y., Ma, L., You, X.M. and Li, L.Q. (2015) Efficacy of Hepatic Resection vs Transarterial Chemoembolization for Solitary Huge Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 9630-9637.
https://doi.org/10.3748/wjg.v21.i32.9630
|
[15]
|
彭一晟, 何攀, 朱刚, 等. CalliSpheres载药微球与传统经肝动脉化疗栓塞术治疗肝细胞癌效果和安全性比较的Meta分析[J]. 临床肝胆病杂志, 2021, 37(8): 1841-1847.
|
[16]
|
Luz, J., Veloso Gomes, F., Costa, N.V., et al. (2021) BestFLR Trial: Liver Regeneration at CT before Major Hepatectomies for Liver Cancer—A Randomized Controlled Trial Comparing Portal Vein Embolization with N-Butyl-Cya- noacrylate Plus Iodized Oil versus Polyvinyl Alcohol Particles Plus Coils. Radiology, 299, 715-724.
https://doi.org/10.1148/radiol.2021204055
|
[17]
|
倪俊声, 李曜, 葛乃建, 等. ALPPS与采用不同栓塞材料PVE对肝再生及手术切除率影响研究[J]. 中国实用外科杂志, 2021, 41(9): 1043-1048+1055.
|
[18]
|
Chan, A., Zhang, W.Y., Chok, K., et al. (2021) ALPPS versus Portal Vein Embolization for Hepatitis-Related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant before Major Hepatectomy. Annals of Surgery, 273, 957-965. https://doi.org/10.1097/SLA.0000000000003433
|
[19]
|
Schnitzbauer, A.A., Lang, S.A., Goessmann, H., et al. (2012) Right Portal Vein Ligation Combined with in Situ Splitting Induces Rapid Left Lateral Liver Lobe Hyper-trophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings. Annals of Surgery, 255, 405-414. https://doi.org/10.1097/SLA.0b013e31824856f5
|
[20]
|
Cai, X., Tong, Y., Yu, H., et al. (2017) The ALPPS in the Treatment of Hepatitis B-Related Hepatocellular Carcinoma with Cirrhosis: A Single-Center Study and Literature Review. Surgical innovation, 24, 358-364.
https://doi.org/10.1177/1553350617697187
|
[21]
|
Lang, H. (2020) ALPPS—Beneficial or Detrimental. Surgical Oncology, 33, 249-253.
https://doi.org/10.1016/j.suronc.2019.10.013
|
[22]
|
Li, Q.J., He, M.K., Chen, H.W., et al. (2022) Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 40, 150-160.
https://doi.org/10.1200/JCO.21.00608
|
[23]
|
Zhu, X.D., Huang, C., Shen, Y.H., et al. (2021) Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 10, 320-329.
https://doi.org/10.1159/000514313
|
[24]
|
韦滔, 唐置鸿, 韦猛, 等. TACE联合TKI及PD-1抑制剂在不可切除肝细胞癌患者转化治疗中的疗效[J]. 中国癌症防治杂志, 2021, 13(4): 413-419.
|
[25]
|
Ren, Z., Xu, J., Bai, Y., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study. The Lancet. Oncology, 22, 977-990. https://doi.org/10.1016/S1470-2045(21)00252-7
|